Has James Daugherty, MD received payments from drug or device companies?

Yes. Drug and device makers reported $119,460 in general payments to James Daugherty, MD across 554 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Daugherty, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Daugherty, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Daugherty, MD

Medical Oncology · Florence, ALNPI 1598727083

Payments from drug & device makers

$119,460in general payments, 2019–2025

Across 554 payments — averaging $215.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$106K
Amgen$3K
Novartis$1K
E.r. Squibb & Sons, L.L.C.$1K
AstraZeneca$925
Pharmacyclics LLC, An Abbvie Company$884
plus $6K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	50	$105,980
Amgen	31	$2,941
Novartis	85	$1,415
E.r. Squibb & Sons, L.L.C.	10	$1,316
AstraZeneca(2 entities)	55	$925
Pharmacyclics LLC, An Abbvie Company	20	$884
Pfizer	35	$651
Incyte Corporation	14	$355
Johnson & Johnson	18	$353
Daiichi Sankyo Inc.	19	$338
Exelixis Inc.	15	$313
Lilly USA, LLC	19	$289
Boehringer Ingelheim	11	$250
Eisai Inc.	14	$246
Genentech USA, Inc.	11	$217
Seagen Inc.	12	$201
Sobi, Inc	4	$176
Gilead(2 entities)	11	$162
Bayer	8	$153
Takeda Pharmaceuticals U.S.A., Inc.	7	$147
Sanofi	6	$139
Astellas Pharma US Inc	7	$127
Bristol Myers Squibb	6	$126
AbbVie	6	$123
Beigene USA, Inc.	6	$117
GSK	6	$96
Dova Pharmaceuticals	4	$95
Array Biopharma Inc	5	$89
Pharmaessentia USA Corporation	3	$86
Jazz Pharmaceuticals Inc.	4	$85
Regeneron Healthcare Solutions, Inc.	4	$71
Octapharma USA, Inc.	1	$67
Coherus Oncology, Inc.	3	$58
Puma Biotechnology, Inc.	3	$58
Clovis Oncology, Inc.	3	$57
Ipsen Biopharmaceuticals, Inc	3	$57
Shield Therapeutics Inc	2	$50
Servier Pharmaceuticals LLC	2	$48
Stemline Therapeutics Inc.	2	$44
Silk Road Medical, Inc.	1	$39
Sumitomo Pharma America, Inc.	2	$39
Blueprint Medicines Corporation	2	$39
EMD Serono, Inc.	2	$38
Progenics Pharmaceuticals, Inc.	2	$34
Deciphera Pharmaceuticals Inc.	2	$33
Taiho Oncology, Inc.	2	$33
Mirati Therapeutics, Inc.	1	$27
Tesaro, Inc.	1	$26
Rigel Pharmaceuticals, Inc.	1	$25
Fennec Pharmaceuticals, Inc.	1	$23
AVEO Pharmaceuticals, Inc.	2	$23
Karyopharm Therapeutics Inc.	1	$21
Recordati_rare_diseases_inc.	1	$21
Tosoh Bioscience, Inc.	1	$21
Apellis Pharmaceuticals, Inc.	1	$19
Myovant Sciences Inc.	1	$18
Acrotech Biopharma Inc.	1	$17
Spectrum Pharmaceuticals Inc.	1	$16
EUSA Pharma (US) LLC	1	$15
Kyowa Kirin, Inc.	1	$14

How this compares

$119,460 in reported general payments places this provider in the 75th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$682,972

Medicare patients

332

Services billed

27,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Florence

Syed Abbas AliJasper$3M
Joelle HamiltonHomewood$2.2M
Sachin PaiMobile$2.1M
Marshall SchreederHuntsville$1.1M
Pranitha ProdduturvarMobile$910K
John DubayTuscaloosa$756K
Sunil RangarajanBirmingham$576K
Hemant PatelMuscle Shoals$61K
Johnny NacillaCullman$23K
Michael GarciaJasper$23K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →